ReviewInternational journal of general medicine2026
Multimodal Neuroimaging Mechanisms of Apathy in Alzheimer's Disease: A Narrative Review of Structural, Functional, and Molecular Evidence.
Review in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apathy is the most common neuropsychiatric symptom in Alzheimer's disease (AD) and is conceptualized as a pathological reduction of goal-directed motivation and behavior. It is currently believed that apathy has an independent neurobiological basis rather than merely accompanying cognitive decline. This narrative review synthesizes evidence from structural, functional, and molecular neuroimaging studies published up to 2025, identified through targeted PubMed searches and reference tracking, without applying formal systematic inclusion/exclusion criteria. Existing imaging evidence indicates that the core mechanism of apathy lies in the specific impairment of the prefrontal-basal ganglia motivational circuit: gray matter atrophy and hypometabolism in the anterior cingulate cortex (ACC) and orbitofrontal cortex are closely associated with impaired motivation integration and reward evaluation, whereas structural damage to the dorsolateral prefrontal cortex contributes to executive planning deficits. Functional network analysis further reveals suppression of the default mode network and ineffective compensation of the central executive network. Molecular imaging studies confirm that structural degeneration of the locus coeruleus, dopaminergic presynaptic transmission dysfunction, and synergistic pathological accumulation of amyloid-beta and Tau proteins in the motivational circuit collectively constitute the neurobiological basis of apathy. Furthermore, computational modeling has already been employed as an analytical framework to dissect these mechanisms, revealing altered effort-based decision-making and abnormal frontoparietal connectivity. Given the frequent impairment in self-awareness (anosognosia) regarding their own apathy in AD, informant-based assessments are essential for accurate clinical evaluation. Ultimately, integrating these multimodal biomarkers may facilitate early identification and stratified interventions, including dopaminergic and noradrenergic pharmacotherapies as well as non-invasive brain stimulation techniques such as transcranial magnetic stimulation (TMS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.